Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice-Reference-Cited by-同舟云学术

Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice

Published:2016-06-10 Issue:6 Volume:11 Page:e0157125
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Nath Kavindra,Nelson David S.,Putt Mary E.,Leeper Dennis B.,Garman Bradley,Nathanson Katherine L.,Glickson Jerry D.

Funder

National Cancer Institute

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference63 articles.

1. Cancer statistics, 2006;A Jemal;CA Cancer J Clin,2006

2. Inhibition of mutated, activated BRAF in metastatic melanoma;KT Flaherty;N Engl J Med,2010

3. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma;AX Wang;IUBMB Life,2013

4. Genomic correlates of response to CTLA4 blockade in metastatic melanoma;EM Van Allen;Science,2015

5. Checkpoint inhibitors in the treatment of cutaneous malignant melanoma;J Lutzky;Chin Clin Oncol,2014

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lonidamine Increases the Cytotoxic Effect of 1-[(4-Amino-2-methyl-5-pyrimidinyl)methyl]-3-(2-chloroethyl)-3-nitrosourea via Energy Inhibition, Disrupting Redox Homeostasis, and Downregulating MGMT Expression in Human Lung Cancer Cell Line;ACS Omega;2024-08-17

2. Energy Blocker Lonidamine Reverses Nimustine Resistance in Human Glioblastoma Cells through Energy Blockade, Redox Homeostasis Disruption, and O⁶-Methylguanine-DNA Methyltransferase Downregulation: In Vitro and In Vivo Validation;ACS Pharmacology & Translational Science;2024-04-17

3. pH-dependent structural characteristics of lonidamine: ¹H and ¹³C NMR study;RSC Advances;2023

4. The Potential of Lonidamine in Combination with Chemotherapy and Physical Therapy in Cancer Treatment;Cancers;2020-11-11

5. Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?;Chemical Reviews;2019-01-14